Just recently, we published our monthly shortlist of wide-moat companies passing our rigorous 3-step stock selection process exclusive for Seeking Alpha readers. Following our latest coverage of biotech giant Bristol-Myers Squibb (BMY), we decided to assess another leading pharmaceutical company, Pfizer (PFE), to see whether it fares favorably in our shareholder value focused framework.

In light of Buffett’s teachings distilled from his 50+ years of shareholder letters, our analysis is based on the three dimensions that truly matter: operations, capital allocation, and valuation. Before we do that, however, let’s jump into what makes Pfizer an interesting candidate today.

READ FULL ARTICLE HERE